_Recent research has reaffirmed the efficacy of radioiodine (RAI) therapy in improving survival rates for patients with differentiated thyroid cancer (DTC), particularly among those classified as high-risk. A comprehensive study utilizing data from over 101,000 patients in the Surveillance, Epidemiology, and End Results (SEER) Program found that RAI therapy significantly enhanced relative survival rates across various risk categories. Notably, high-risk patients experienced a remarkable relative survival benefit of up to 30.9%, while even low-risk groups, such as those with minimally invasive follicular thyroid cancer, showed a 2.0% improvement over a 10-year period. _
These findings challenge previous uncertainties regarding the role of RAI in low- and intermediate-risk DTC cases. The study’s robust methodology, which stratified patients by histological subtype and risk level, provides compelling evidence supporting the broader application of RAI therapy. The observed survival benefits underscore the importance of individualized treatment strategies and suggest that RAI therapy may be underutilized in certain patient populations. This research offers valuable insights for clinicians in optimizing treatment plans and improving long-term outcomes for DTC patients.
